Medical devices, healthcare technology and the business of care
PMA approval · P030017

PRECISION SPINAL CORD STIMULATION(SCS) SYSTEM

Boston Scientific Corp · Decision date Apr 27, 2004

MEDTECHLEDGER EXPLANATIONP030017

What did the FDA approve?

The FDA database entry records an original PMA approval, dated April 27, 2004, for the Precision Spinal Cord Stimulation (SCS) System from Boston Scientific Corp. The decision field states approval for the device as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.

The entry contains no supplement type or supplement reason, so this is not a change to a previously approved system. The statement reports the device's indicated purpose as written in the approval record; it does not by itself provide independent evidence of safety or clinical effectiveness. No additional technical specifications, trial data, or labeling details beyond the quoted indication are present in the source fields.

FDA approval order statement

APPROVAL FOR THE PRECISION SPINAL CORD STIMULATION (SCS) SYSTEM. THE DEVICE IS INDICATED AS AN AID IN THE MANAGEMENT OF CHRONIC INTRACTABLE PAIN OF THE TRUNK AND/OR LIMBS, INCLUDING UNILATERAL OR BILATERAL PAIN ASSOCIATED WITH THE FOLLOWING: FAILED BACK SURGERY SYNDROME, INTRACTABLE LOW BACK PAIN AND LEG PAIN.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Apr 27, 2004

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P030017
Regulatory pathway
Premarket approval application
Product code
LGW
Decision code
APPR
Decision date
Apr 27, 2004
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P030017 received

    Application receipt date recorded by FDA.

  2. P030017 · FDA decision

    APPR

  3. P030017/S396 · Related supplement

    WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems

  4. P030017/S399 · Related supplement

    Precision Spectra SCS Systems; Precision Novi SCS Systems; Precision Montage MRI SCS Systems; Spectra Wave Writer SCS Sy

Timeline entries are records held by MedtechLedger for P030017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030017

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
25155 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records